Marketed Drugs

• When there is a compelling need defined as:

  • the drug or biological product offers a “Meaningful Therapeutic Benefit” AND the absence of labeling poses a risk
    • Or
  • “Substantial Use” AND the absence of labeling poses a risk

Previous slide

Next slide

Back to first slide

View graphic version